Medigene AG Company Description

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer.

The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications.

Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications.

The company also develops MDG2011, MDG2021, MDG2012, MDG20XX, and MDG10xx to treat multiple solid tumors.

It has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors.

It has operations in Germany, the United States, and Asia. The company has research collaboration with WuXi Biologics to design and co-research TCR-guided T Cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors.

Medigene AG was founded in 1994 and is headquartered in Munich, Germany.

Medigene AG

Country	Germany
Founded	1994
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	76
CEO	Selwyn Ho

Contact Details

Address: Lochhamer Strasse 11 Munich, 82152 Germany
Phone	49 89 2000 330
Website	medigene.com

Stock Details

Ticker Symbol	0QGJ
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	DE000A1X3W00
SIC Code	2836

Key Executives

Name	Position
Dr. Dolores J. Schendel	Chief Executive Officer, Chief Scientific Officer and Member of Executive Management Board
Dr. Ernst-Ludwig Winnacker	Co-Founder and Chairman Scientific Advisory Board
Dr. Birger Kohlert	Chief Financial Officer
Dr. Anna Niedl	Vice President Investor Relations and Corporate Communications
Dr. Rene Goedkoop	Acting Chief Medical Officer